Amgen Commits to PhRMA's Enhanced Code on Interactions with Healthcare Professionals as Part of the Company's 'Clearly Amgen' Initiative Read more about Amgen Commits to PhRMA's Enhanced Code on Interactions with Healthcare Professionals as Part of the Company's 'Clearly Amgen' Initiative
New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab) Read more about New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting Read more about Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting Read more about Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP Read more about Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP
Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference Read more about Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference
Amgen Names Anna Richo Senior Vice President of Worldwide Compliance Read more about Amgen Names Anna Richo Senior Vice President of Worldwide Compliance
2008 Recipients of Amgen Award for Science Teaching Excellence Announced Read more about 2008 Recipients of Amgen Award for Science Teaching Excellence Announced
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers Read more about Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy Read more about Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
